Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study

Authors: Vincenzo Dario Mandato, Enrico Farnetti, Federica Torricelli, Martino Abrate, Bruno Casali, Gino Ciarlini, Debora Pirillo, Maria Carolina Gelli, Davide Nicoli, Mario Grassi, Giovanni Battista LA Sala, Stefano Palomba

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients.

Methods

Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients’ genotype on overall survival and progression free survival were our main outcome measures.

Results

A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival.

Conclusions

rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.
Literature
1.
Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, et al. Two estrogen related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the epidemiology of endometrial cancer consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:242–7.CrossRefPubMedPubMedCentral
2.
Kato N, Motoyama T. Expression of hepatocyte nuclear factor-1β in human urogenital tract during the embryonic stage. Anal Quant Cytol Histol. 2009;3:34–40.
3.
Bernardini L, Gimelli S, Gervasini C, Carella M, Baban A, Frontino G, et al. Recurrent microdeletion at 17q12 as a cause of Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome: two case reports. Orphanet J Rare Dis. 2009;4:25.CrossRefPubMedPubMedCentral
4.
Oram RA, Edghill EL, Blackman J, Taylor MJ, Kay T, Flanagan SE, et al. Mutations in the hepatocyte nuclear factor-1β (HNF1B) gene are common with combined uterine and renal malformations but are not found with isolated uterine malformations. Am J Obstet Gynecol. 2010;203:e1–5.CrossRefPubMed
5.
Granberg CF1, Harrison SM, Dajusta D, Zhang S, Hajarnis S, Igarashi P, et al. Genetic basis of prune belly syndrome: screening for HNF1A gene. J Urol. 2012;187:272–8.CrossRefPubMed
6.
Cuff J1, Salari K, Clarke N, Esheba GE, Forster AD, Huang S, et al. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One. 2013;8:e74562.CrossRefPubMedPubMedCentral
7.
Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255–8.CrossRefPubMed
8.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;14:1532–43.CrossRef
9.
Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580–7.CrossRefPubMed
10.
Kato N, Motoyama T. Hepatocyte nuclear factor-1beta(HNF-1beta) in human urogenital organs: its expression and role in embryogenesis and tumorigenesis. Histol Histopathol. 2009;24:1479–86.PubMed
11.
Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013;26:1594–604.CrossRefPubMed
12.
Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O’Mara T. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43:451–4.CrossRefPubMedPubMedCentral
13.
Matise TC, Ambite JL, Buyske S, Carlson CS, Cole SA, Crawford DC, et al. The Next PAGE in understanding complex traits: design for the analysis of Population Architecture using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol. 2011;174:849–59.CrossRefPubMedPubMedCentral
14.
Setiawan VW, Haessler J, Schumacher F, Cote ML, Deelman E, Fesinmeyer MD, et al. HNF1B and endometrial cancer risk: results from the PAGE study. PLoS One. 2012;7:e30390.CrossRefPubMedPubMedCentral
15.
Kolonel LN1, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151:346–57.CrossRefPubMedPubMedCentral
16.
The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109.CrossRef
17.
Bach I, Yaniv M. More potent transcriptional activators or a transdominant inhibitor of the HNF1 homeoprotein family are generated by alternative RNA processing. EMBO J. 1993;12:4229–42.PubMedPubMedCentral
18.
De Vivo I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, Australian National Endometrial Cancer Study Group, et al. Genome-wide association study of endometrial cancer in E2C2. Hum Genet. 2014;133:211–24.CrossRefPubMed
19.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. PLoS Med. 2007;4, e296.CrossRef
20.
Mandato VD, Formisano D, Pirillo D, Ciarlini G, Cerami LB, Ventura A, et al. Province wide clinical governance network for clinical audit for quality improvement in endometrial cancer management. Int J Gynecol Cancer. 2012;22:94–100.CrossRefPubMed
21.
Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:35–9.CrossRef
22.
Palomba S, Mandato VD, La Sala G. New surgical approaches to early-stage endometrial cancer. In: Diaz-Padilla I, Garcia-Donas J, editors. Endometrial cancer: a comprehensive clinical and translational update. New York: Nova Science Publishers; 2014. p. 117–46.
23.
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2010;108:176.CrossRef
24.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–41.CrossRefPubMed
25.
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–12.CrossRefPubMedPubMedCentral
26.
Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma - diagnostic utility of HNF1B and estrogen receptor. Histopathology. 2014;64:585–96.CrossRefPubMed
27.
Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, et al. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 (vHNF1) in ovarian cancer. Cancer Res. 2009;69:4843–50.CrossRefPubMedPubMedCentral
28.
Shigetomi H, Sudo T, Shimada K, Uekuri C, Tsuji Y, Kanayama S, et al. Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: chemosensitivity is regulated by checkpoint kinase CHK1. Int J Gynecol Cancer. 2014;24:838–43.CrossRefPubMed
29.
Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012;109:11252–7.CrossRefPubMedPubMedCentral
30.
Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M, et al. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer. Oncol Rep. 2014;32:979–88.PubMed
31.
Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25:282–8.PubMed
32.
Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol. 2013;26:428–34.CrossRefPubMed
33.
Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625–32.CrossRefPubMedPubMedCentral
34.
Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328–33.CrossRefPubMed
35.
Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, et al. Wholeexome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22:2120–9.CrossRefPubMedPubMedCentral
36.
Girouard J, Lafleur MJ, Parent S, Leblanc V, Asselin E. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells. Gynecol Oncol. 2013;128:335–43.CrossRefPubMed
37.
Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004;94:785–95.CrossRefPubMed
38.
Yang Q, Yamagata K, Fukui K, Cao Y, Nammo T, Iwahashi H, et al. Hepatocyte nuclear factor-1alpha modulates pancreatic beta-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes. 2002;51:1785–92.CrossRefPubMed
39.
Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlein B, Furth EE, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001;7:1133–7.CrossRefPubMed
40.
Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol. 2012;124:354–65.CrossRefPubMed
Metadata
Title
HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study
Authors
Vincenzo Dario Mandato
Enrico Farnetti
Federica Torricelli
Martino Abrate
Bruno Casali
Gino Ciarlini
Debora Pirillo
Maria Carolina Gelli
Davide Nicoli
Mario Grassi
Giovanni Battista LA Sala
Stefano Palomba
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1246-5

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Texture analysis on MR images helps predicting non-response to NAC in breast cancer

Research article

Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation

Research Article

Prediction of resistance to chemotherapy in ovarian cancer: a systematic review

Research article

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo

Research article

Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth

Research article

Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits